Evidence map›Paper›PMID 42434847›Full record

Trial reportFuture oncology (London, England)2026

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed

Pau Montesinos, Jessica K Altman, Lars Bullinger, June-Won Cheong, Amir T Fathi, Mark J Levis, Selina Luger, Toshihiro Miyamoto, Esther Natalie Oliva, Alexander E Perl and 14 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Pau MontesinosDepartment of Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain.
Jessica K AltmanDivision of Hematology Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Lars BullingerDepartment of Hematology, Oncology and Tumor immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.
June-Won CheongDepartment of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea (South).
Amir T FathiDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Mark J LevisDivision of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA.
Selina LugerDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Toshihiro MiyamotoDepartment of Hematology, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Esther Natalie OlivaDepartment of Hematology, London North West University Healthcare NHS Trust, London, UK.
Alexander E PerlDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christian RécherCentre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France.
Rebeca Rodriquez VeigaDepartment of Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain.
Jianxiang WangNational Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Amer M ZeidanDivision of Hematologic Malignancies, Yale School of Medicine, New Haven, CT, USA.
Li LiuDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Yvonne DuongDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Jaime E Connolly RohrbachDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Giorgio InghiramiDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Karenza AlexisDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Andreas GosbergDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Akash NaharDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Kristy BurnsDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Harry P ErbaDepartment of Medicine, Duke University Cancer Institute, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quizartinib is a potent type II inhibitor of FMS-like tyrosine kinase 3 (FLT3) that demonstrated significant survival benefit among patients with newly diagnosed (ND) acute myeloid leukemia (AML) without

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzothiazolesfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcutePhenylurea CompoundsProtein Kinase InhibitorsAdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultBenzothiazolesFLT3 protein, humanfms-Like Tyrosine Kinase 3Phenylurea CompoundsProtein Kinase InhibitorsquizartinibAcute myeloid leukemiaclinical trialFLT3-FLT3 inhibitoroverall survivalquizartinib

Identifiers

PMID42434847
PMCPMC13390524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.